Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT06293118

The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease

Conditions: Parkinson Disease

Sex: All
Ages: 40 Years – 90 Years
Healthy volunteers: No
Phase: NA
Enrollment: 34
Sponsor: Hospital Israelita Albert Einstein

Summary

Ischemic conditioning (IC) is a promising therapy that can mimic the physiological effects of physical exercise. IC consists of using a cuff to measure blood pressure and calibrate 200 mmHg on the upper or lower limb. Thus, at alternating intervals of 5 minutes, ischemia or reperfusion occurs, depending on whether the cuff is inflated or deflated. IC induces changes in spinal cord excitability for the last reflex reactions of recruited motoneurons with improved balance control in healthy young people and improved learning in the elderly. The objective of the present study is to evaluate the chronic effect of IC on the motor function and cognitive performance of patients with Parkinson's disease. Furthermore, the investigators will evaluate secondary outcomes such as mobility, quality of life, and immunological responses.

Eligibility Criteria

Inclusion Criteria: * PD patients aged 40 years or older; * Diagnosis of PD without cognitive complaints or with complaints, but without impact on daily activities; Exclusion Criteria: * Patients with uncontrolled diabetes mellitus or peripheral neuropathy; * Uncontrolled arterial hypertension (BP\>160/100mmHg); * Uncontrolled diabetes (Fasting glucose \> 250mg/dl, peripheral retinopathy or diabetic ketoacidosis); * Uncontrolled dyslipidemia (total chol \> 220mg/dL); * Pre-existing autoimmune diseases; * Infectious conditions for less than 1 month; * Neurological problems that prevent training from being carried out; * History of anemia, cerebral vascular disease, myocardial infarction in the last 6 months; * Previous deep vein thrombosis; * Smoking \< 6 months; * Symptomatic peripheral arterial obstructive disease; * Cognitive dysfunction: Moca \< 24.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06293118). StuddyBuddy aggregates publicly available trial information.